Lymphoma, Mantle-Cell: Clinical Trials

1,214 trials for Lymphoma, Mantle-Cell, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

679 completed, 167 terminated, 115 recruiting, 88 unknown. 605 Phase 2, 518 Phase 1, 86 Phase 3, 71 Not applicable, 15 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2605Completed 336, Terminated 80, Recruiting 61, Active not recruiting 50, Unknown 41, Withdrawn 23, Not yet recruiting 14
Phase 1518Completed 296, Terminated 82, Recruiting 51, Active not recruiting 32, Unknown 29, Withdrawn 24, Not yet recruiting 3, Enrolling by invitation 1
Phase 386Completed 46, Unknown 20, Terminated 6, Active not recruiting 5, Recruiting 5, Withdrawn 3, Not yet recruiting 1
Not applicable71Completed 39, Terminated 15, Withdrawn 7, Recruiting 4, Not yet recruiting 3, Unknown 2, Enrolling by invitation 1
Early Phase 115Completed 8, Terminated 3, Unknown 3, Active not recruiting 1
Phase 46Completed 5, Not yet recruiting 1

Follow Lymphoma, Mantle-Cell: new trials by email Literature Review of Lymphoma, Mantle-Cell trials Research Report on Lymphoma, Mantle-Cell

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.
CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies
Phase 1Not yet recruitingGUSTAVO SALGUERO122027-04-012026-10-20
Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial
Polatuzumab Vedotin, Acalabrutinib, Mosunetuzumab - Mantle Cell Lymphoma
Phase 2Not yet recruitingUniversity of Washington272027-03-012026-11-02
Study to Evaluate the Clinical Impact of Bruton's Tyrosin Kinase (BTK) Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice
Mantle Cell Lymphoma
Not yet recruitingFondazione Italiana Linfomi - ETS5002027-03-012026-11-19
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Phase 1 / Phase 2RecruitingCity of Hope Medical Center582026-12-212026-10-22
Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure
Pirtobrutinib, Sonrotoclax, Rituximab injection - Mantle Cell Lymphoma (MCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital352026-12-082026-11-18
A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma
Zanubrutinib, Obinutuzumab, Sonrotoclax - Mantle Cell Lymphoma
Phase 2Not yet recruitingMemorial Sloan Kettering Cancer Center452026-12-012026-11-04
Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy
Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Phase 2RecruitingUniversity of Michigan Rogel Cancer Center262026-11-102026-11-18
A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma
TT-01488 Tablets, Rituximab, Immunomodulatory Agent - Mantle Cell Lymphoma (MCL)
Phase 2Not yet recruitingTransThera Sciences (Nanjing), Inc.1882026-10-102026-10-02
Simulation-Free Single-Fraction Radiation Therapy for Indolent Lymphoma
Simulation-Free Single-Fraction Radiation Therapy (4 Gy × 1) - Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma
Not applicableRecruitingUniversity Health Network, Toronto602026-10-092026-11-18
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
ICP-248, Pirtobrutinib, Orelabrutinib - Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Phase 3Not yet recruitingBeijing InnoCare Pharma Tech Co., Ltd.2802026-10-012026-08-25
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Phase 1RecruitingCity of Hope Medical Center102026-09-292026-10-14
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Phase 2RecruitingVanderbilt-Ingram Cancer Center592026-09-252026-10-02
This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R
ARI-0001 T cells with anti-CD19 chimeric antigen receptor (CAR-T) - Adult B-cell Acute Lymphoblastic Leukemia, Follicular Lymphoma (FL)
Not applicableNot yet recruitingGUSTAVO SALGUERO122026-09-012026-02-17
Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL
zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine - Mantle Cell Lymphoma (MCL)
Phase 2Not yet recruitingMiltenyi Biomedicine GmbH522026-09-012026-05-06
Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics
Glofitamab - Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma
Phase 2Not yet recruitingJoshua Brody162026-09-012026-08-05
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma
Phase 1RecruitingPaolo Caimi, MD152026-09-012026-09-09
A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
7×19-THEMIS CAR-T cells - Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 1 / Phase 2RecruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine702026-09-012026-08-26
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Zanubrutinib, Sonrotoclax, CAR-T Cell Therapy - Mantle Cell Lymphoma
Phase 2RecruitingCanadian Cancer Trials Group402026-08-242026-10-14
Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy
Atrial Fibrillation (AF), Chronic Lymphocytic Leukemia
Not yet recruitingTina Baykaner5002026-08-012026-07-17
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
Nemtabrutinib, Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus) - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Phase 2RecruitingVanderbilt-Ingram Cancer Center252026-07-312026-08-17

Showing 20 of 1214. Sign in to see all of them.

Narrower conditions

Lymphoma, Follicular (752)  ·  Lymphoma, Large B-Cell, Diffuse (704)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (669)  ·  Lymphoma, B-Cell, Marginal Zone (625)  ·  Lymphoma, Non-Hodgkin (617)  ·  Burkitt Lymphoma (507)  ·  Lymphoma (488)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (482)  ·  Lymphoma, Large-Cell, Immunoblastic (437)  ·  Hodgkin Disease (384)  ·  Waldenstrom Macroglobulinemia (313)  ·  Multiple Myeloma (284)  ·  Lymphoma, T-Cell, Cutaneous (261)  ·  Leukemia, Myeloid, Acute (251)

Broader conditions

Hemic and Lymphatic Diseases (1214)  ·  Neoplasms by Histologic Type (1210)  ·  Immunoproliferative Disorders (1209)  ·  Lymphatic Diseases (1209)  ·  Immune System Diseases (1208)  ·  Lymphoproliferative Disorders (1174)  ·  Neoplasms (1145)  ·  Hematologic Diseases (753)  ·  Lymphoma, B-Cell (737)  ·  Pathologic Processes (735)  ·  Pathological Conditions, Signs and Symptoms (735)  ·  Disease Attributes (730)  ·  Lymphoma (726)  ·  Leukemia, Lymphoid (713)  ·  Chronic Disease (680)

Interventions

Rituximab (230)  ·  Cyclophosphamide (204)  ·  fludarabine phosphate (108)  ·  Peripheral Blood Stem Cell Transplantation (103)  ·  Filgrastim (87)  ·  Etoposide (76)  ·  Cytarabine (71)  ·  ibrutinib (68)  ·  Mycophenolic Acid (67)  ·  Bortezomib (66)  ·  Cyclosporine (63)  ·  Whole-Body Irradiation (63)  ·  Lenalidomide (60)  ·  Melphalan (59)  ·  Bendamustine Hydrochloride (58)

Sponsors

National Cancer Institute (NCI) (100)  ·  Fred Hutchinson Cancer Center (70)  ·  M.D. Anderson Cancer Center (47)  ·  City of Hope Medical Center (41)  ·  Memorial Sloan Kettering Cancer Center (32)  ·  Masonic Cancer Center, University of Minnesota (26)  ·  Case Comprehensive Cancer Center (24)  ·  Mayo Clinic (22)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (17)  ·  Alliance for Clinical Trials in Oncology (16)  ·  Roswell Park Cancer Institute (15)  ·  Barbara Ann Karmanos Cancer Institute (13)  ·  Jonsson Comprehensive Cancer Center (13)  ·  National Institutes of Health Clinical Center (CC) (13)  ·  University of Nebraska (13)

Countries

United States (904)  ·  China (95)  ·  France (81)  ·  Italy (81)  ·  Germany (74)  ·  United Kingdom (63)  ·  Canada (56)  ·  Spain (56)  ·  Australia (47)  ·  Poland (39)  ·  South Korea (35)  ·  Belgium (32)  ·  Japan (29)  ·  Israel (24)  ·  Switzerland (24)

Top investigators

Ajay Gopal (10)  ·  Brenda Sandmaier (8)  ·  Julie M Vose, MD (7)  ·  David Maloney (6)  ·  Christos E. Emmanouilides, MD (5)  ·  Claudio G. Brunstein, MD, PhD (5)  ·  Roger Strair, MD, PhD (5)

Results publications

PMID 34515338, PMID 32499241, PMID 34398557, PMID 17242396, PMID 19238148, PMID 19949018, PMID 20028764, PMID 20032498, PMID 22002018, PMID 22337718, PMID 23834234, PMID 24591201, PMID 24687837, PMID 25381051, PMID 27118452, PMID 30782611, PMID 32126141, PMID 32242358, PMID 32888407, PMID 33735476, PMID 34780125, PMID 34797699, PMID 36375120, PMID 36485104, PMID 38669626, PMID 10552943, PMID 10673703, PMID 10764422, PMID 11410496, PMID 11756154, PMID 12171484, PMID 12525530, PMID 12620412, PMID 12735303, PMID 12907446, PMID 1403051, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15107815, PMID 15459300, PMID 15466923, PMID 15570084, PMID 15598978, PMID 15817673, PMID 16030029, PMID 16061911, PMID 16116429, PMID 16123218, PMID 16135477

NIH funding

P30CA033572 (32), P30CA015704 (26), P30CA043703 (20), P30CA015083 (19), P30CA006973 (12), P30CA022453 (12), U10CA032102 (11), 2023 (10), P30CA016672 (10), P30CA036727 (10), 2015 (9), P30CA072720 (9), U01CA076576 (9), P01CA018029 (8), U10CA031946 (8)